Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.14
CPHI's Cash-to-Debt is ranked lower than
83% of the 799 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.05 vs. CPHI: 0.14 )
Ranked among companies with meaningful Cash-to-Debt only.
CPHI' s Cash-to-Debt Range Over the Past 10 Years
Min: 0  Med: 0.37 Max: No Debt
Current: 0.14
Equity-to-Asset 0.74
CPHI's Equity-to-Asset is ranked higher than
67% of the 731 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.64 vs. CPHI: 0.74 )
Ranked among companies with meaningful Equity-to-Asset only.
CPHI' s Equity-to-Asset Range Over the Past 10 Years
Min: -10  Med: 0.81 Max: 0.97
Current: 0.74
-10
0.97
Debt-to-Equity 0.22
CPHI's Debt-to-Equity is ranked higher than
61% of the 568 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.30 vs. CPHI: 0.22 )
Ranked among companies with meaningful Debt-to-Equity only.
CPHI' s Debt-to-Equity Range Over the Past 10 Years
Min: -2.12  Med: 0.04 Max: 1.53
Current: 0.22
-2.12
1.53
Piotroski F-Score: 5
Altman Z-Score: 0.63
Beneish M-Score: -3.64
WACC vs ROIC
9.55%
-11.01%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % -51.73
CPHI's Operating Margin % is ranked lower than
83% of the 758 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.95 vs. CPHI: -51.73 )
Ranked among companies with meaningful Operating Margin % only.
CPHI' s Operating Margin % Range Over the Past 10 Years
Min: -175.11  Med: 18.99 Max: 38.71
Current: -51.73
-175.11
38.71
Net Margin % -57.79
CPHI's Net Margin % is ranked lower than
84% of the 759 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.06 vs. CPHI: -57.79 )
Ranked among companies with meaningful Net Margin % only.
CPHI' s Net Margin % Range Over the Past 10 Years
Min: -178.69  Med: 16.11 Max: 38.63
Current: -57.79
-178.69
38.63
ROE % -13.76
CPHI's ROE % is ranked lower than
78% of the 780 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.91 vs. CPHI: -13.76 )
Ranked among companies with meaningful ROE % only.
CPHI' s ROE % Range Over the Past 10 Years
Min: -35.05  Med: 8.99 Max: 42.3
Current: -13.76
-35.05
42.3
ROA % -10.20
CPHI's ROA % is ranked lower than
78% of the 805 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.71 vs. CPHI: -10.20 )
Ranked among companies with meaningful ROA % only.
CPHI' s ROA % Range Over the Past 10 Years
Min: -28.38  Med: 8.14 Max: 35.5
Current: -10.2
-28.38
35.5
ROC (Joel Greenblatt) % -21.85
CPHI's ROC (Joel Greenblatt) % is ranked lower than
77% of the 793 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 13.48 vs. CPHI: -21.85 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
CPHI' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -46.65  Med: 14.99 Max: 41.47
Current: -21.85
-46.65
41.47
3-Year Revenue Growth Rate -22.00
CPHI's 3-Year Revenue Growth Rate is ranked lower than
91% of the 634 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.10 vs. CPHI: -22.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
CPHI' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -13.5 Max: 179.1
Current: -22
0
179.1
3-Year EBITDA Growth Rate -33.60
CPHI's 3-Year EBITDA Growth Rate is ranked lower than
95% of the 601 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.90 vs. CPHI: -33.60 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
CPHI' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -33.6  Med: -13.8 Max: 25.1
Current: -33.6
-33.6
25.1
3-Year EPS without NRI Growth Rate -23.00
CPHI's 3-Year EPS without NRI Growth Rate is ranked lower than
84% of the 576 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.60 vs. CPHI: -23.00 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
CPHI' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -36.5  Med: -8.75 Max: 19.8
Current: -23
-36.5
19.8
GuruFocus has detected 1 Warning Sign with China Pharma Holding Inc $CPHI.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» CPHI's 30-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

CPHI Guru Trades in Q3 2016

Jim Simons 120,100 sh (+26.02%)
» More
Q4 2016

CPHI Guru Trades in Q4 2016

Jim Simons 133,600 sh (+11.24%)
» More
Q1 2017

CPHI Guru Trades in Q1 2017

Jim Simons 169,400 sh (+26.80%)
» More
Q2 2017

CPHI Guru Trades in Q2 2017

Jim Simons 338,000 sh (+99.53%)
» More
» Details

Insider Trades

Latest Guru Trades with CPHI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412    SIC: 2834
Compare:SGX:AYL, SGX:BFK, NAS:BSPM, HKSE:08225, OTCPK:SUWN, HKSE:08197, SHSE:600385, SZSE:300254, SHSE:600421, SZSE:300239, SZSE:002693, SHSE:600513, SHSE:603811, SHSE:600671, SZSE:000153, HKSE:01349, SHSE:600080, SZSE:000705, SZSE:000809, SHSE:600222 » details
Traded in other countries:XQJ.Germany,
Headquarter Location:China
China Pharma Holding Inc develops, manufactures and markets pharmaceutical products for human use in connection with a high-incidence and high-morality diseases and medical conditions in the People's Republic of China.

China Pharma Holding, Inc., a Delaware corporation was incorporated on January 28, 1999 under the name 'Softstone, Inc.' On March 16, 2006; it changed its corporate name to China Pharma Holdings, Inc. The company develops, manufactures and markets pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions in the People's Republic of China (the 'PRC'). All of its operations are conducted in the PRC, where its manufacturing facilities are located. It manufactures pharmaceutical products in the form of dry powder injectibles, liquid injectibles, tablets, capsules, oral solutions and granules. All of its pharmaceutical products are sold on a prescription basis and have been approved for at least one or more therapeutic indications by the Chinese State Food and Drug Administration (the 'SFDA') based upon demonstrated safety and efficacy. At December 31, 2012, it manufactured 20 pharmaceutical products for a variety of diseases and medical indications. It markets and sells its products through 16 sales offices covering all major cities and provinces in the PRC. Its product portfolio includes both branded and generic drugs that it either developed or was developed by it in joint research efforts with its academic institutional partners or, to a lesser extent, acquired from third parties. It develops new products in-house as well as through relationships with several research institutes, including the Chinese Academy of Sciences, China University of Pharmaceuticals, Sichuan University, Chongqing Medical Industry Institute and the Military Medical Academy Basic Medical Science Institute. The Company sells its prescription drugs to hospitals and clinics through its distribution system which is comprised of 1,220 independent regional distributors. In November 2008, it purchased the patented medical formula for a cerebral/cardio-vascular indication and the manufacturing processes for that product candidate from a third party laboratory. In connection with that acquisition, it obtained the title of the patent. This patent expires in 2025. At December 31, 2012, it owned 17 registered trademarks, including marks for nine of the 20 pharmaceutical products it manufacture, including the tradenames Funalin, Fukexing, Beisha, Shiduotai, Xinuo, Pusenlitai, Pusenouke, Shuchang and Shenkaineng, as well as marks for its AFGF logo, its HPS logo, its two HELPSON logos and four other logos.

Ratios

vs
industry
vs
history
PB Ratio 0.15
CPHI's PB Ratio is ranked higher than
99% of the 751 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.80 vs. CPHI: 0.15 )
Ranked among companies with meaningful PB Ratio only.
CPHI' s PB Ratio Range Over the Past 10 Years
Min: 0.06  Med: 0.21 Max: 4.2
Current: 0.15
0.06
4.2
PS Ratio 0.60
CPHI's PS Ratio is ranked higher than
89% of the 736 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.97 vs. CPHI: 0.60 )
Ranked among companies with meaningful PS Ratio only.
CPHI' s PS Ratio Range Over the Past 10 Years
Min: 0.16  Med: 0.74 Max: 4.41
Current: 0.6
0.16
4.41
Price-to-Free-Cash-Flow 6.45
CPHI's Price-to-Free-Cash-Flow is ranked higher than
90% of the 208 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 25.89 vs. CPHI: 6.45 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
CPHI' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 2.04  Med: 6.13 Max: 456
Current: 6.45
2.04
456
Price-to-Operating-Cash-Flow 5.56
CPHI's Price-to-Operating-Cash-Flow is ranked higher than
88% of the 277 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.02 vs. CPHI: 5.56 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
CPHI' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 1.21  Med: 5.31 Max: 45.97
Current: 5.56
1.21
45.97
EV-to-EBIT -2.63
CPHI's EV-to-EBIT is ranked lower than
99.99% of the 559 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 20.11 vs. CPHI: -2.63 )
Ranked among companies with meaningful EV-to-EBIT only.
CPHI' s EV-to-EBIT Range Over the Past 10 Years
Min: -23.7  Med: 1.5 Max: 12.8
Current: -2.63
-23.7
12.8
EV-to-EBITDA -4.38
CPHI's EV-to-EBITDA is ranked lower than
99.99% of the 587 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.50 vs. CPHI: -4.38 )
Ranked among companies with meaningful EV-to-EBITDA only.
CPHI' s EV-to-EBITDA Range Over the Past 10 Years
Min: -14.8  Med: 2.1 Max: 21.6
Current: -4.38
-14.8
21.6
EV-to-Revenue 1.35
CPHI's EV-to-Revenue is ranked higher than
82% of the 755 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.22 vs. CPHI: 1.35 )
Ranked among companies with meaningful EV-to-Revenue only.
CPHI' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.2  Med: 1.3 Max: 4.7
Current: 1.35
0.2
4.7
Shiller PE Ratio 3.67
CPHI's Shiller PE Ratio is ranked higher than
99% of the 198 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 39.37 vs. CPHI: 3.67 )
Ranked among companies with meaningful Shiller PE Ratio only.
CPHI' s Shiller PE Ratio Range Over the Past 10 Years
Min: 1  Med: 2.32 Max: 4.6
Current: 3.67
1
4.6
Current Ratio 1.64
CPHI's Current Ratio is ranked lower than
67% of the 782 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.40 vs. CPHI: 1.64 )
Ranked among companies with meaningful Current Ratio only.
CPHI' s Current Ratio Range Over the Past 10 Years
Min: 0.01  Med: 4.66 Max: 23.65
Current: 1.64
0.01
23.65
Quick Ratio 0.95
CPHI's Quick Ratio is ranked lower than
76% of the 782 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.82 vs. CPHI: 0.95 )
Ranked among companies with meaningful Quick Ratio only.
CPHI' s Quick Ratio Range Over the Past 10 Years
Min: 0.01  Med: 3.12 Max: 17.34
Current: 0.95
0.01
17.34
Days Inventory 256.23
CPHI's Days Inventory is ranked lower than
90% of the 707 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 117.36 vs. CPHI: 256.23 )
Ranked among companies with meaningful Days Inventory only.
CPHI' s Days Inventory Range Over the Past 10 Years
Min: 138.59  Med: 246.11 Max: 375
Current: 256.23
138.59
375
Days Sales Outstanding 78.88
CPHI's Days Sales Outstanding is ranked lower than
61% of the 651 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 74.70 vs. CPHI: 78.88 )
Ranked among companies with meaningful Days Sales Outstanding only.
CPHI' s Days Sales Outstanding Range Over the Past 10 Years
Min: 78.88  Med: 280.49 Max: 502.3
Current: 78.88
78.88
502.3
Days Payable 70.48
CPHI's Days Payable is ranked higher than
62% of the 600 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 70.96 vs. CPHI: 70.48 )
Ranked among companies with meaningful Days Payable only.
CPHI' s Days Payable Range Over the Past 10 Years
Min: 6.15  Med: 32.87 Max: 90.42
Current: 70.48
6.15
90.42

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 0.15
CPHI's Price-to-Tangible-Book is ranked higher than
100% of the 690 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.51 vs. CPHI: 0.15 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
CPHI' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.06  Med: 0.4 Max: 6.1
Current: 0.15
0.06
6.1
Price-to-Intrinsic-Value-Projected-FCF 0.24
CPHI's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
97% of the 328 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.31 vs. CPHI: 0.24 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
CPHI' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.08  Med: 0.31 Max: 4.24
Current: 0.24
0.08
4.24
Price-to-Median-PS-Value 0.80
CPHI's Price-to-Median-PS-Value is ranked higher than
72% of the 712 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.09 vs. CPHI: 0.80 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
CPHI' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.22  Med: 1.57 Max: 82.5
Current: 0.8
0.22
82.5
Earnings Yield (Greenblatt) % -38.02
CPHI's Earnings Yield (Greenblatt) % is ranked lower than
95% of the 805 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.10 vs. CPHI: -38.02 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CPHI' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -150.4  Med: 12.6 Max: 139.1
Current: -38.02
-150.4
139.1
Forward Rate of Return (Yacktman) % -35.97
CPHI's Forward Rate of Return (Yacktman) % is ranked lower than
97% of the 380 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.46 vs. CPHI: -35.97 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
CPHI' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -36  Med: -1.8 Max: 41.5
Current: -35.97
-36
41.5

More Statistics

Revenue (TTM) (Mil) $14.59
EPS (TTM) $ -0.19
Beta2.13
Short Percentage of Float0.65%
52-Week Range $0.15 - 0.35
Shares Outstanding (Mil)43.58
» More Articles for CPHI

Headlines

Articles On GuruFocus.com
China Pharma Holdings, Inc. Announces Notification of NYSE American Listing Deficiency Sep 12 2017 
China Pharma Holdings, Inc. Reports Second Quarter 2017 Financial Results Aug 15 2017 
CPHI to Hold Second Quarter 2017 Earnings Conference Call On Tuesday August 15, 2017 at 8:30 a.m. ET Aug 08 2017 
China Pharma Holdings, Inc. Reports First Quarter 2017 Financial Results May 12 2017 
CPHI to Hold First Quarter 2017 Earnings Conference Call On Friday May 12, 2017 at 8:30 a.m. ET May 08 2017 

More From Other Websites
Corporate News Blog - GlaxoSmithKline Declares Publication of Phase-III Results Of Mepolizumab in... Sep 14 2017
China Pharma Holdings, Inc. Announces Notification of NYSE American Listing Deficiency Sep 12 2017
China Pharma Holdings, Inc. :CPHI-US: Earnings Analysis: Q2, 2017 By the Numbers : August 16, 2017 Aug 16 2017
China Pharma Holdings, Inc. Reports Second Quarter 2017 Financial Results Aug 15 2017
CPHI to Hold Second Quarter 2017 Earnings Conference Call On Tuesday August 15, 2017 at 8:30 a.m. ET Aug 08 2017
Top 3 Healthcare Penny Stocks for 2017 Jun 20 2017
China Pharma Holdings, Inc. :CPHI-US: Earnings Analysis: Q1, 2017 By the Numbers : May 24, 2017 May 24 2017
China Pharma Holdings, Inc.'s Wholly-owned Subsidiary Participated in PharmChina/API China... May 17 2017
China Pharma Holdings, Inc. Reports First Quarter 2017 Financial Results May 12 2017
CPHI to Hold First Quarter 2017 Earnings Conference Call On Friday May 12, 2017 at 8:30 a.m. ET May 08 2017
China Pharma Holdings, Inc. :CPHI-US: Earnings Analysis: Q4, 2016 By the Numbers : April 4, 2017 Apr 04 2017
China Pharma Holdings, Inc. Reports Full Year 2016 Financial Results Mar 31 2017
CPHI to Hold Fiscal Year 2016 Earnings Conference Call On Friday March 31, 2017 at 8:30 a.m. ET Mar 27 2017
China Pharma Holdings, Inc. :CPHI-US: Earnings Analysis: Q3, 2016 By the Numbers : November 18, 2016 Nov 18 2016
China Pharma Holdings, Inc. Reports Third Quarter Financial Results Nov 15 2016
CPHI to Hold Third Quarter 2016 Earnings Conference Call On Tuesday November 15, 2016 at 8:30 a.m.... Nov 07 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}